2021-05-09 GP (HK)’s Blockbuster Product SIR-Spheres® Y-90 Resin Microspheres Completes the First Patient Administration

2021-04-20 GP (HK)’s Global Innovation Product STC3141 Receives Approval for a Phase IIa Clinical Trial of COVID-19 in Belgium

2021-03-19 GP (HK) Announces 2020 Annual Results Profit

2021-03-09 SIR-Spheres® Y-90 Resin Microspheres Obtains Recommendation from NICE and Approval from the FDA

2021-03-04 GP (HK)’s Independently Developed Innovative Glaucoma Treatment Drug Obtained Drug Registration Certificate

2021-03-04 GP (HK)’s First-In-Class Drug STC3141 for Sepsis has been Granted A “Notice of Approval for Clinical Trial of Drugs” Issued by the NMPA

2021-02-21 GP (HK) Announces Positive Profit Alert

2020-12-13 First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141 Promote Commercialization

2020-11-25 NDA for Y-90 Resin Microspheres of GP(HK) Accepted by NMPA and NDA for Prostate Cancer Imaging RDC Product TLX591-CDx Accepted by FDA

2020-11-13 First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141

2020-11-09 Strategic Cooperation with Nanospectra and BlackSwan Expands the Group’s Product Portfolio in Precision Interventional Diagnostics and Treatment

2020-11-01 GP(HK) Enters into A Few Agreements in the Field of Cancer Diagnostics and Treatment Introduce Multiple RDC and Strengthen Strategic Planning and Innovation in Anti-tumor Field